Literature DB >> 30811287

Adjuvant Systemic Treatment of Premenopausal Women With Hormone Receptor-Positive Early Breast Cancer: Lights and Shadows.

Meredith M Regan1, Gini F Fleming2, Barbara Walley3, Prudence A Francis4, Olivia Pagani5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30811287      PMCID： PMC6455715          DOI： 10.1200/JCO.18.02433

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  26 in total

1.  Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

Authors:  Soonmyung Paik; Gong Tang; Steven Shak; Chungyeul Kim; Joffre Baker; Wanseop Kim; Maureen Cronin; Frederick L Baehner; Drew Watson; John Bryant; Joseph P Costantino; Charles E Geyer; D Lawrence Wickerham; Norman Wolmark
Journal:  J Clin Oncol       Date:  2006-05-23       Impact factor: 44.544

2.  Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study.

Authors:  G M H E Dackus; K Jóźwiak; G S Sonke; E van der Wall; P J van Diest; M Hauptmann; S Siesling; S C Linn
Journal:  Eur J Cancer       Date:  2017-12-21       Impact factor: 9.162

3.  Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial.

Authors:  Georg Pfeiler; Robert Königsberg; Christian Fesl; Brigitte Mlineritsch; Herbert Stoeger; Christian F Singer; Sabine Pöstlberger; Guenther G Steger; Michael Seifert; Peter Dubsky; Susanne Taucher; Hellmut Samonigg; Vesna Bjelic-Radisic; Richard Greil; Christian Marth; Michael Gnant
Journal:  J Clin Oncol       Date:  2011-05-09       Impact factor: 44.544

4.  Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.

Authors:  Poornima Saha; Meredith M Regan; Olivia Pagani; Prudence A Francis; Barbara A Walley; Karin Ribi; Jürg Bernhard; Weixiu Luo; Henry L Gómez; Harold J Burstein; Vani Parmar; Roberto Torres; Josephine Stewart; Meritxell Bellet; Antonia Perelló; Faysal Dane; Antonio Moreira; Daniel Vorobiof; Michelle Nottage; Karen N Price; Alan S Coates; Aron Goldhirsch; Richard D Gelber; Marco Colleoni; Gini F Fleming
Journal:  J Clin Oncol       Date:  2017-06-27       Impact factor: 44.544

5.  70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

Authors:  Fatima Cardoso; Laura J van't Veer; Jan Bogaerts; Leen Slaets; Giuseppe Viale; Suzette Delaloge; Jean-Yves Pierga; Etienne Brain; Sylvain Causeret; Mauro DeLorenzi; Annuska M Glas; Vassilis Golfinopoulos; Theodora Goulioti; Susan Knox; Erika Matos; Bart Meulemans; Peter A Neijenhuis; Ulrike Nitz; Rodolfo Passalacqua; Peter Ravdin; Isabel T Rubio; Mahasti Saghatchian; Tineke J Smilde; Christos Sotiriou; Lisette Stork; Carolyn Straehle; Geraldine Thomas; Alastair M Thompson; Jacobus M van der Hoeven; Peter Vuylsteke; René Bernards; Konstantinos Tryfonidis; Emiel Rutgers; Martine Piccart
Journal:  N Engl J Med       Date:  2016-08-25       Impact factor: 91.245

6.  Adjuvant ovarian suppression in premenopausal breast cancer.

Authors:  Prudence A Francis; Meredith M Regan; Gini F Fleming; István Láng; Eva Ciruelos; Meritxell Bellet; Hervé R Bonnefoi; Miguel A Climent; Gian Antonio Da Prada; Harold J Burstein; Silvana Martino; Nancy E Davidson; Charles E Geyer; Barbara A Walley; Robert Coleman; Pierre Kerbrat; Stefan Buchholz; James N Ingle; Eric P Winer; Manuela Rabaglio-Poretti; Rudolf Maibach; Barbara Ruepp; Anita Giobbie-Hurder; Karen N Price; Marco Colleoni; Giuseppe Viale; Alan S Coates; Aron Goldhirsch; Richard D Gelber
Journal:  N Engl J Med       Date:  2014-12-11       Impact factor: 91.245

Review 7.  Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression.

Authors:  Harold J Burstein; Christina Lacchetti; Holly Anderson; Thomas A Buchholz; Nancy E Davidson; Karen E Gelmon; Sharon H Giordano; Clifford A Hudis; Alexander J Solky; Vered Stearns; Eric P Winer; Jennifer J Griggs
Journal:  J Clin Oncol       Date:  2016-02-16       Impact factor: 44.544

8.  Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

Authors:  Olivia Pagani; Meredith M Regan; Barbara A Walley; Gini F Fleming; Marco Colleoni; István Láng; Henry L Gomez; Carlo Tondini; Harold J Burstein; Edith A Perez; Eva Ciruelos; Vered Stearns; Hervé R Bonnefoi; Silvana Martino; Charles E Geyer; Graziella Pinotti; Fabio Puglisi; Diana Crivellari; Thomas Ruhstaller; Eric P Winer; Manuela Rabaglio-Poretti; Rudolf Maibach; Barbara Ruepp; Anita Giobbie-Hurder; Karen N Price; Jürg Bernhard; Weixiu Luo; Karin Ribi; Giuseppe Viale; Alan S Coates; Richard D Gelber; Aron Goldhirsch; Prudence A Francis
Journal:  N Engl J Med       Date:  2014-06-01       Impact factor: 91.245

9.  Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.

Authors:  Meredith M Regan; Prudence A Francis; Olivia Pagani; Gini F Fleming; Barbara A Walley; Giuseppe Viale; Marco Colleoni; István Láng; Henry L Gómez; Carlo Tondini; Graziella Pinotti; Karen N Price; Alan S Coates; Aron Goldhirsch; Richard D Gelber
Journal:  J Clin Oncol       Date:  2016-04-04       Impact factor: 44.544

10.  Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93.

Authors:  Beat Thürlimann; Karen N Price; Richard D Gelber; Stig B Holmberg; Diana Crivellari; Marco Colleoni; John Collins; John F Forbes; Monica Castiglione-Gertsch; Alan S Coates; Aron Goldhirsch
Journal:  Breast Cancer Res Treat       Date:  2008-02-08       Impact factor: 4.872
View more
  4 in total

Review 1.  Inflammatory Breast Cancer: a Separate Entity.

Authors:  Jennifer M Rosenbluth; Beth A Overmoyer
Journal:  Curr Oncol Rep       Date:  2019-08-15       Impact factor: 5.075

2.  Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT.

Authors:  Olivia Pagani; Prudence A Francis; Gini F Fleming; Barbara A Walley; Giuseppe Viale; Marco Colleoni; István Láng; Henry L Gómez; Carlo Tondini; Graziella Pinotti; Angelo Di Leo; Alan S Coates; Aron Goldhirsch; Richard D Gelber; Meredith M Regan
Journal:  J Clin Oncol       Date:  2019-10-16       Impact factor: 44.544

3.  HER2 positivity is not associated with adverse prognosis in high-risk estrogen receptor-positive early breast cancer patients treated with chemotherapy and trastuzumab.

Authors:  Shuai Li; Jiayi Wu; Ou Huang; Jianrong He; Li Zhu; Weiguo Chen; Yafen Li; Xiaosong Chen; Kunwei Shen
Journal:  Breast       Date:  2020-10-15       Impact factor: 4.380

4.  Major depressive symptoms in breast cancer patients with ovarian function suppression: a cross-sectional study comparing ovarian ablation and gonadotropin-releasing hormone agonists.

Authors:  Junhan Jiang; Junnan Xu; Li Cai; Li Man; Limin Niu; Juan Hu; Tao Sun; Xinyu Zheng
Journal:  BMC Psychiatry       Date:  2021-12-11       Impact factor: 3.630
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.